Philip Band

CEO Philip Band, PhD

Dr. Band is a co-inventor of the CytoDel technology and a co-founder of CytoDel. Dr. Band has extensive bench-to-bedside experience in biotechnology startups as former Vice President Research of Biomatrix, an NYSE company acquired by Genzyme in 2000. The products developed by Dr. Band are now marketed by Sanofi, and are among the best selling products in the US for treating osteoarthritis of the knee. Dr. Band has published more than 60 peer-reviewed research studies in both basic and clinical sciences, and has been issued 15 US patents to date. Dr. Band is a Senior Advisor to the Center for Clinical Research, NYU-Hospital for Joint Diseases, and is on the faculty of the Departments of Orthopedic Surgery, Biochemistry and Molecular Pharmacology, NYU School of Medicine.

Konstantin Ichtchenko

CSO Konstantin Ichtchenko, PhD

Dr. Ichtchenko a co-inventor of the CytoDel technology and a co-founder of CytoDel. He is the Principal Investigator on the funded $7 million NIH multi-center grant supporting development of the CytoDel technology. Dr. Ichtchenko is a widely acknowledged expert on protein engineering, and the molecular mechanisms of inter-neuronal and neuromuscular communication. He was responsible for the first successful expression and crystallographic characterization of the LDL receptor extracellular domain, done in collaboration with three Nobel laureates. Dr. Ichtchenko has also made major contributions to the discovery of neuroligins, molecules that are involved in synaptogenesis, and with yet another Nobel laureate, to the pre- and post-synaptic mechanisms of action of alpha-latrotoxin (black widow spider toxin). He is currently on the faculty of the Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine.

Gordon Beck

Operations Director Gordon Beck, PhD

Dr. Beck has more than 20 years experience of Business Development, Project Leadership and Drug Product R&D from both small Biotech and large Pharma. Major projects include leading the divestment of Roche's RNA therapeutics business and leading the Tamiflu® licensing team in support of the Pandemic Preparedness Taskforce. Dr. Beck serves on the New York University Venture Fund Biotech Review Board, is a Pharmacist by training and has a Ph.D. in Cell Biology, both from Aston University, U.K.

Lee McDonald

Regulatory and Quality Advisor Lee McDonald, PhD

Dr. McDonald has more than 20 years of experience in biomedical product R&D, QA/QC, and IND Regulatory Affairs. He has participated in the translational research and development of more than 50 products from laboratory research to FDA-cleared IND applications and first-in-human clinical trials, most recently as Head of the Investigational Products Core Facility at Memorial Sloan Kettering Cancer Center. For these projects, he developed and implemented manufacturing quality systems, designed and oversaw IND-enabling R&D studies, and wrote IND applications. Dr. McDonald has an undergraduate degree in Chemistry, a PhD in Biomedical Sciences, and post-doctoral training in protein biochemistry and cellular signaling.